EUCTR2012-000933-37-GR进行中（未招募）不适用
Phase II trial of ofatumumab combined with ESHAP as salvage therapy before autologous stem cell transplantation, for patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) previously treated with a rituximab based regimen. - OFA-ESHAP in DLBC
ational and Kapodostrian University of Athens0 个研究点开始时间: 2012年8月9日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Signed and dated written informed consent prior to performing any study-specific procedures.
- •- Adult patients, age range 18-65 years old, eligible for transplantation. Patients > 65 and = 70 years old with ECOG =2 and absence of comorbidities will be included in the study upon investigator’s judgment.
- •- Histologically confirmed diagnosis of relapsed or refractory CD20 positive DLBCL. Diagnosis should be confirmed by immunophenotyping by staining paraffin embedded tissue sections with the following panel of markers: BCL2, CD5, CD10, CD3, CD4, CD8, BCL6, IRF4/MUM-1, Ki67, p53, ALK, HLA class I and HLA-DR.
- •- First relapse after CR or less than PR after first line treatment.
- •- Previous treatment with chemotherapy regimen containing anthracyclines with rituximab for at least 3 cycles.
- •- ECOG Performance Status 0-2.
- •- Life expectancy of more than 3 months.
- •- Adequate bone marrow, liver and renal function:
- •* Hemoglobin = 9.0 g/dL.
- •* Absolute neutrophil count (ANC) = 1500/µl.
- •* Platelet count = 100000/µl.
- •* Total bilirubin = 1.5 X ULN.
- •* AST and ALT = 2.5 x ULN.
- •* Alkaline phosphatase = 1.5 x ULN.
- •* Serum creatinine < 1.5 x ULN.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 31
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Burkitt, mantle-cell and T cell Lymphoma.
- •- CD20 negative DLBCL.
- •- Central nervous system and/or bone marrow involvement.
- •- Prior transplantation.
- •- No prior treatment with anthracycline-containing regimen.
- •- Treatment with rituximab or treatment with rituximab for less than 3 cycles.
- •- Other past or current malignancy with the exception of cured (minimum 2 years prior entry) basal cell carcinoma of the skin, or in situ carcinoma of the cervix or the breast.
- •- History of significant cerebrovascular disease or event with significant symptoms or sequelae.
- •- Any major organ dysfunction.
- •- History of HIV infection.
- •- Patients who have current active hepatic or biliary disease (with exception of patients with Gilbert’s syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment).
- •- Chronic or current infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, tuberculosis and active Hepatitis C.
- •- Positive serology for Hepatitis B (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive and HBsAb negative, a HB DNA test will be performed and if positive the patient will be excluded. Note: If HBcAb positive and HBsAb positive, which is indicative of a past infection, the patient can be included.
- •- Positive serology for hepatitis C (HC) defined by positive test for HCAb, in which case reflexively perform a HC RIBA immunoblot assay on the same sample to confirm the result.
- •- Previous treatment or known or suspected hypersensitivity to ofatumumab.
- •- Known or suspected hypersensitivity to any of the components of the ESHAP regimen.
- •- Treatment with any investigational drug substance or experimental therapy within 4 weeks prior to the 1st treatment cycle, or current participation in any other interventional clinical trial.
- •- Known or suspected inability to comply with study protocol.
- •- Lactating women, women with a positive pregnancy test at screening or women (of childbearing potential) as well as men with female partners of childbearing potential, who are not willing to use adequate contraception from study start through one year following last treatment dose. Adequate contraception is defined as abstinence, oral hormonal birth control, hormonal birth control injections, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, intrauterine device, and male partner sterilization if male partner is sole partner for that patient. The double barrier method can be used in regions where considered acceptable and adequate (condom or occlusive cap plus spermicidal agent).
研究者
相似试验
进行中（未招募）
1 期
Study to evaluate the efficacy and safety of a therapy consisting in combination of two drugs Ofatumumab and Ibrutinib followed by bone marrow transplant taken from donor or consolidation for pretreated high risk patients with Chronic Lymphocytic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864Chronic Lymphocytic LeukemiaEUCTR2015-000684-13-ITFONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS80
进行中（未招募）
1 期
Phase II Trial of Single Agent Ofatumumab in Relapsed / Refractory Mantle Cell Lymphoma - Ofatumumab StudyRelapsed or refractory Mantle Cell LymphomaMedDRA version: 14.1 Level: PT Classification code 10026800 Term: Mantle cell lymphoma recurrent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: PT Classification code 10026801 Term: Mantle cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017675-16-GBPlymouth Hospitals NHS Trust34
进行中（未招募）
1 期
Phase II trial of ofatumumab, dexamethasone and lenalidomide for high-risk CLL (NCRI CLL210) - CLL210 (OfaDexRev)Chronic lymphocytic leukaemia / Small Lymphocytic LymphomaMedDRA version: 18.0 Level: LLT Classification code 10008976 Term: Chronic lymphocytic leukemia System Organ Class: 100000004864MedDRA version: 18.0 Level: LLT Classification code 10041152 Term: Small lymphocytic lymphoma, consistent with CLL (Working Formulation) System Organ Class: 100000004864EUCTR2010-019575-29-GBniversity of Liverpool64
已完成
2 期
Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)Diffuse Large B-cell LymphomaNCT02412267National Cancer Centre, Singapore17
进行中（未招募）
1 期
Ofatumumab in patients with lymphoma of the of the mucosa associated lymphoid tissue (MALT-Lymphoma)YMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT-LYMPHOMA)MedDRA version: 16.0Level: PTClassification code 10061850Term: Extranodal marginal zone B-cell lymphoma (MALT type)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-005223-32-ATMedizinische Universität Wien, Klinik für Innere Medizin I, Abt. Onkologie